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Variants of uncertain signiﬁcanceAutosomal dominant polycystic kidney disease (ADPKD) is a common, monogenic multi-systemic disorder
characterized by the development of renal cysts and various extrarenal manifestations. Worldwide, it is a
common cause of end-stage renal disease. ADPKD is caused by mutation in either one of two principal genes,
PKD1 and PKD2, but has large phenotypic variability among affected individuals, attributable to PKD genic and
allelic variability and, possibly, modiﬁer gene effects. Recent studies have generated considerable information
regarding the genetic basis and molecular diagnosis of this disease, its pathogenesis, and potential strategies
for targeted treatment. The purpose of this article is to provide a comprehensive review of the genetics of
ADPKD, includingmechanisms responsible for disease development, the role of gene variations andmutations
in disease presentation, and the putative role of microRNAs in ADPKD etiology. The emerging and important
role of genetic testing and the advent of novel molecular diagnostic applications also are reviewed. This article
is part of a Special Issue entitled: Polycystic Kidney Disease.stic Kidney Disease.
+1 212 746 4483.
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Autosomal dominant polycystic kidney disease (ADPKD) is a
monogenic multi-systemic disorder characterized by the develop-
ment of renal cysts and various extrarenal manifestations. It is the
most common inherited renal disease with a prevalence of approx-
imately 1 in 400 to 1 in 1000 live births in all races [1–4]. It affects
approximately 600,000 Americans and 12.5 million individuals
worldwide, with 5000 to 6000 new cases diagnosed in the United
States each year. About 50% of patients with ADPKD will progress
to end stage renal disease (ESRD) by the age of 60 years, with
hemodialysis or kidney transplant being the only available treatments
[5]. Although ADPKD accounts for 4.4% of all patients requiring renal
replacement therapy [6], it is characterized by considerable pheno-
typic variability, ranging from presentation in utero with enlarged,
cystic kidneys to incidental diagnosis in the elderly with adequate
renal function [7]. Hypertension is present in about 50% of ADPKD
patients age 20–30 years with clinically normal renal function [8];
this is approximately one decade earlier than the onset of primary
hypertension in the general population. Extrarenal manifestations
include cysts in the liver, pancreas, seminal vesicles and arachnoid
membranes. The prevalence of intracranial aneurysm is about ﬁve
times higher than in the general population and is associated with
signiﬁcant morbidity and mortality [9].2. ADPKD genes and proteins
ADPKD is a genetically heterogeneous, caused by mutations in
two genes: PKD1 located on chromosome 16p13.3 [10] and PKD2
located on 4q21 [11]. It is uncertain whether a third PKD gene is
present in a small number of unlinked families. PKD1 has 46 exons
and encompasses 50 kb of genomic DNA, encoding a large transcript
with an open reading frame of 12,909 bp. The ﬁrst 33 exons of 5' PKD1
are located in a region that is duplicated six times and located ~13–16
MB distal to PKD1 on chromosome 16 [12]. This region has 97–99%
homology to the six PKD1 pseudogenes, thereby considerably com-
plicating genetic testing [13]. PKD2 is a single-copy gene that has 15
exons, spanning 68 kb of genomic sequence, encoding a 2904 bp
open reading frame transcript [11]. In clinical identiﬁed populations,
PKD1 mutations were found to account for 85% of cases and the
remaining 15% of patients had PKD2mutations, while in community-
based studies, PKD2 mutations accounted for approximately 29–36%
of cases [14] [4]. This discrepancy is considered to be due to the later
onset of renal cyst development and delayed detection of patients
with the milder phenotype associated with PKD2. In approximately
10% of affected individuals there is no prior family history of ADPKD,
suggesting the presence of de novo PKD gene mutations [15].
The PKD1 gene product, polycystin-1 (PC1), is a large integral
membrane protein with 11 transmembrane domains; approximately
75% of the entire protein is located in a large extracellular region
consisting of a variety of domains and a short cytoplasmatic tail
(Fig. 1). The extracelluar NH2-terminal domain contains protein
motifs important in protein-protein interactions, including 12 PKD
domains (immunoglobulin-like folds), a receptor egg jelly domain
Fig. 1. Structure of polycystin-1 and polycystin-2 proteins. PC1 and PC2 interact through their respective coiled-coil domains in the C-terminal tails [24]. Cleavage of the
intramembranous COOH-terminal fragment of PC1 has been proposed to be important in gene transcription [19]. Details of the domains and regions of homology are shown in the
key. Abbreviations: GPS, GPCR proteolytic site; REJ, receptor egg jelly; WSC, cell wall integrity and stress-response component 1; PLAT, polycystin, lipoxygenase, and alpha toxin;
PKD, polycystic kidney disease; LDL-A, low density lipoprotein class A; ER, endoplasmic reticulum. This graph was generated by using ExPASY Proteomics Server PROSITE module
with some modiﬁcations (http://expasy.org/cgi-bin/prosite/ScanView.cgi?scanﬁle=41542972408.scan.gz).
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protein can undergo autoproteolytic cleavage at the GPS site, which
may be important to activate the protein [16]. The C-terminal tail of
PC1 can be cleaved and migrate into the nucleus, where it has been
proposed to be important in gene transcription [19]. Overall PC1 has
the structure of a receptor (of an unidentiﬁed ligand) or adhesion
molecule [20]. The PKD2 protein, polycystin-2 (PC2) belong to a TRPP
subfamily of transient receptor potential channels (TRPP2) [4] and
is a nonselective cation channel that transports calcium [21]. PC2
contains a short N-terminal cytoplasmatic region, six transmembrane
domains that are homologous with a portion of the transmembrane
domain of PCI, and a short C-terminal fragment (Fig. 1) [11,22]. PC1,
PC2, and proteins associatedwith other renal cystic disease, have been
localized to immotile cilia on renal tubule and other epithelium [23].
PC1 and PC2 can interact with each other to form a complex structure
within the primary cilium [24,25]. A current hypothesis is that the
polycystin complex is a mechanoreceptor that senses ﬂuid ﬂow in
the tubular lumen, triggering Ca2+ inﬂux through the TRPP2 channel,
consequently affecting the levels of intracellular calcium and cyclic
AMP (cAMP) [26]. Abnormal cross-talk between the adenylate cyclase
and receptor tyrosine kinase pathways, together with reduced intra-
cellular calcium concentration, promote renal tubular epithelial cell
proliferation and ﬂuid secretion, which are key features of the ADPKD
phenotype [27] [28].
3. Genetic mechanism of pathogenesis
The focal development of renal cysts and the great variability in
the size of cysts can be explained by a two-hit model, which has
been demonstrated in both orthologous mouse models and ADPKD
patients: a germline and a somatic mutation inactivate the PKD alleles
separately [29] [30]. The germline mutation inherited from the affected
parent, theﬁrst hit, is necessary, but not sufﬁcient for cyst formation. The
ﬁrst hit exists in all cells including, renal tubular epithelium. The secondhit, a somatic mutation in an individual tubular cell, inactivates the
normalPKD1orPKD2 allele, thus allowingabnormal focalproliferationof
renal tubular cells and cyst formation [31] [32]. The existence of both a
germline and a somatic mutation in PKD1 or PKD2 is indicative of a
cellular recessive model that has been postulated to reduce the
expression levels of PC1 or PC2, resulting in the development of cysts.
Theoretically, the somaticmutation can occur at any time and anywhere
on PKD1 or PKD2 genes. Bilineal inheritance of certain PKD1 and PKD2
mutationsdemonstrated that co-inheritance of amutation in both genes
was not lethal during embryogenesis, but was associated with a more
severe disease phenotype [33].
Homozygosity of PKD1 or PKD2mutations, or compound heterozy-
gosity ofmutations in PKD1 and PKD2 genes orthologousmousemodels
results in an embryonic lethal phenotype [29,34,35], whereas hetero-
zygous mice develop only a few cysts at an older age [36]. Conditional
knockout of Pkd1 inmice indicated a developmental switch at postnatal
day 13; inactivating Pkd1 before this time point resulted inmore rapidly
progressive cystic disease [37]. Two PKD animalmodels generated from
homozygous hypomorphic alleles (see below) that generate only
13–20% of the normally spliced mRNA product, resulted in dose
reduction of the protein, indicating that cysts can develop even if the
synthesis of intact protein does not cease [38] [39]. By contrast, a
transgenic mouse model over-expressing Pkd1 by 2- to 15-fold above
endogenous protein levels develop renal cystic disease [40], while PKD2
over-expressing transgenic mice have been shown to develop renal
cysts and increased levels of proliferation and apoptosis [41]. Over-
expression of human PKD2 in mice also leads to abnormalities in tubule
morphogenesis [42]. These ﬁndings support a “haploinsufﬁciency”
disease mechanism where a signiﬁcant reduction in the level of the
functional polycystin proteins below a critical threshold is required for
causing cysts formation.
Interestingly, over-expression of truncated Pkd2, lacking the entire
COOH-terminus in transgenic rats causes cyst formation and retinal
degeneration, suggesting a dominant-negative effect possibly due to
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[43]. However, these authors could not rule out a dosage effect caused
by over-expressing the mutant PKD2 cDNA [43]. Taken together,
animal studies suggest that multiple genetic mechanisms that result
in imbalance in the expression of either PC1 or PC2 can affect their
function and cause cystogenesis [44]. The presence of somatic PKD2
mutations detected in cysts of patients with PKD1 germline mutations
further supports the two-hit model and the dosage effect hypothesis
for cyst formation [45].
4. Genotype/phenotype correlation
The phenotypic variability of ADPKD can be explained at three
genetic levels: genic, allelic and genemodiﬁer effects. Genic effects are
attributed to the PKD gene involved. As noted, PKD1 mutations are
associated with more severe disease and earlier mean age of onset
[46]. The mean age of onset of ESRD is approximately 20 years earlier
in patients with PKD1mutations compared to patients withmutations
in PKD2 (54.3 years vs. 74.0 years) [46]. The more severe phenotype
in PKD1 patients is likely due to the development of renal cysts at an
earlier age, rather than a faster rate of cyst growth, accounting for the
younger age of diagnosis of ADPKD and earlier age of onset of ESRD in
the PKD1 population [47,48]. PKD1 patients have a higher incidence of
hypertension and hematuria. An effect of gender has been identiﬁed
in patients with PKD2 mutations: men with PKD2 gene mutations
progress to ESRD more rapidly than women, (68.1 years vs. 76.0
years). No gender difference is demonstrable for PKD1 patients [7,49].
Less is known about the impact of allelic heterogeneity on the
severity of ADPKD. In general, patients with mutation in the 5' region of
PKD1 reach ESRD slightly earlier than patients with mutation in the 3'
region (53 vs. 56 years) [7]. Patients with mutations in the 5' region of
PKD1 also seem to have a higher prevalence of intracranial aneurysms
and aneurysm rupture[50]. No clear correlation has been demonstrated
between severity of disease phenotype and the position of themutation
in PKD2, orwith themutation type in either PKD gene. Recently, Rossetti
et al. described hypomorphic PKD1 and PKD2 alleles (i.e., alleles with
reduced levels of gene activity) in ADPKD patients [51]. The presence
of a heterozygous hypomorphic allele resulted in mild cystic disease.
However, homozygosity or compound heterozygosity of hypomprhic
alleles caused a moderate to severe disease phenotype, with cyst
formation similar to that caused by known PKD gene mutations. It was
proposed that a hypomorphic allele coexisting with a severe disease
allele could cause early onset disease [51,52].
ADPKD is characterized by signiﬁcant intrafamilial phenotypic
variability, both in the rate of progression of chronic kidney disease
and in the array of extrarenal manifestations [53]. Analysis of the
phenotypic variability in renal function between monozygotic twins
and sibs supports a role for genetic modiﬁers [54] [55]. Estimates of
the variability in ESRD development indicate that 18–50% may be due
to heritable modifying factors [56]. Recently, Liu et al. screened 173
candidate genes in a large cohort of 794 patients from 227 families
with PKD1. The researchers found three SNPs in Dickkopf 3 (DKK3)
gene that were only marginally associated with disease severity. No
SNP was signiﬁcantly associated with renal survival [57]. Given these
modest effects, follow-up studies are necessary for verifying the as-
sociation reported [57,58]. With the development of high-resolution
SNP arrays and the availability of clinically well-characterized, large
ADPKD cohorts will enable further properly powered genome-wide
association study (GWAS) for identifying such genes.
5. Genetic variations and mutations in ADPKD
5.1. Gene variations in PKD1 and PKD2
High levels of allelic heterogeneity exists for both PKD genes. There
is no mutation hot spot for PKD1 and PKD2, which means mutationsare usually private, highly variable and spread throughout the entire
gene. The ADPKD Mutation Database at Mayo Clinic (http://www.
pkdb.mayo.edu/) [59], the most complete mutation database for
ADPKD, currently (February 2011) lists mutation information for a
total of 819 families, 616 (75%) of whom have PKD1 mutations and
the remaining 25% of the families have mutations in PKD2. Rossetti
et al. [60] screened 202 probands in the CRISP cohort (Consortium
for Radiological Imaging Studies of Polycystic Kidney Disease), a
longitudinal observational study that enrolled 241 ADPKD individuals
to determine if changes in renal and cyst volumes can be detected over
a short period of time by using high-resolution magnetic resonance
[61]. Deﬁnite pathogenic mutations were identiﬁed in 127 probands
(62.9%), and probably pathogenicmutations (missense, atypical splice
and small in-frame changes) were found in 53 probands (26.2%). Of
these mutations, 153 (85%) were in PKD1 and 27 (15%) were in PKD2.
The total mutation detection rate was 89%, with 70% of the mutations
unique to a single family. A smaller study conducted at Weill Cornell
Medical College using The Rogosin Institute ADPKD Data Repository
patient population reported similar results: 85% were PKD1mutations
and 15% were mutations in PKD2 [62].
The ADPKDMutation Database classiﬁes ADPKD genetic variations
into 12 categories according to their characteristics at the DNA or
protein level. This includes frameshift mutations, nonsensemutations,
splice-site substitutions, IVS (intervening sequence) variations, silent
changes, silent 3' untranslated changes, synonymous changes, and
rearrangements (deletions and duplications) (http://www.pkdb.
mayo.edu/). Variations in PKD genes have been further classiﬁed
into six categories according to their clinical signiﬁcance: deﬁnitely
pathogenic, highly likely pathogenic, likely pathogenic, hypomorphic,
indeterminate and likely neutral. The distinction between “deﬁnitely
pathogenic” and other mutation categories is based on computational
analysis and other contextual information, if available (Table 1). The
ADPKD Mutation Database documents a total of 864 changes for
PKD1 (Table 1). Among these, 50.4 (436) are pathogenic (including
35.6% deﬁnitely pathogenic, 11.3% highly likely pathogenic and 3.5%
likely pathogenic), 0.5% (4) are hypomorphic, 7.8% (67) are
indeterminate and 41.3% (357) are neutral. Large deletions and
duplications account for only 3% of the pathogenicmutations reported
for PKD1. Fig. 2 illustrates the distributions of all known genomic
changes in PKD1 gene. There are 139 PKD2 changes documented in that
database demonstrating a distribution pattern somewhat different
than that observed for PKD1 with a higher percentage of deﬁnite
pathogenic mutations. Among these, 82.7% (115) are pathogenic
(including 69.8% deﬁnitely pathogenic, 6.5% highly likely pathogenic
and 6.5% likely pathogenic), 2.9% (4) are indeterminate and 14.4% (20)
are neutral (Table 1).
PKD1 is signiﬁcantly more polymorphic compared to PKD2: 424
polymorphisms of 864 total changes documented in PKD1 (49%),
whereas only 24 polymorphisms of 139 changes (17%) were reported
for PKD2. The high number of polymorphisms observed in PKD1
supports a high new mutation rate for PKD1. This can be explained, at
least in part, by characteristics of the PKD1 gene: high GC content [63],
the presence of a long polypyrimidine tract in intron 21 [64], and
the multiple reiterations of the 5' region on chromosome 16,
predisposing it to unequal recombination and gene conversion events
[65].
5.2. Alternative splicing in PKD genes
Alternative splicing is an important regulatory mechanism for
controlling gene expression. While atypical splicing gene variants are
mostly documented for pathogenic mutations [66], several naturally
occurring alternatively splicedmRNA species also have been reported.
Hackmann et al. [67] reported the presence of three major and one
minor naturally occurring PKD2/Pkd2 (human/murine) alternative
transcripts. These variants, one lacking half of exon 6 and the other
Table 1
Distribution of PKD1 and PKD2 gene variants by type and pathogenicity.
Deﬁnitely pathogenic Highly likely pathogenic Likely pathogenic Hypomorphic Indeterminate Likely neutral Total
PKD1 Nonsense 110 0 0 0 0 0 110
Frameshift 134 0 0 0 0 0 134
Splice 32 12 1 0 1 0 46
Insertion 3 1 1 0 0 0 5
Deletion 11 15 5 0 0 1 32
Large deletion 15 0 0 0 0 0 15
Large duplication 1 0 0 0 0 0 1
Substitution 2 70 23 4 64 96 259
IVS Silent 0 0 0 0 0 96 96
IVS Unknown 0 0 0 0 2 0 2
3'UTR silent 0 0 0 0 0 6 6
Synonymous 0 0 0 0 0 158 158
Subtotal 308 98 30 4 67 357 864
PKD2 Nonsense 30 0 0 0 0 0 30
Frameshift 50 0 0 0 0 0 50
Splice 14 2 1 0 0 0 17
Insertion 1 0 1 0 0 0 2
Deletion 1 0 3 0 0 0 4
Large deletion 1 0 0 0 0 0 1
Substitution 0 7 4 0 3 9 23
IVS silent 0 0 0 0 0 5 5
IVS unknown 0 0 0 0 1 0 1
Synonymous 0 0 0 0 0 6 6
Subtotal 97 9 9 0 4 20 139
All 405 107 39 4 71 377 1003
IVS, intervening sequence; UTR, untranslated region.
Deﬁnitely pathogenic including nonsense, frameshift, typical splicing and in-fame changes of ﬁve ormore amino acids. The Pathogenicity of other changes were assessed by a scoring
system integrating Grantham matrix score, the likelihood for aberrant splicing, segregation analysis results (if available) and contextual information. A score of ≥11 was classed as
highly likely pathogenic; a score 5 to 10 as likely pathogenic; -4 to 4 as indeterminate; and ≤−5 as likely neutral [60]. Hypomorphic mean incompletely penertrant.
Data derived from the ADPKD Mutation Database (http://www.pkdb.mayo.edu/), February 2011.
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fractions, and, thus, could presumably not be translated into proteins.
Another transcript lacking exon 7 generated signiﬁcant levels of
altered protein but was unable to interact with PC1 in cell culture
expression studies. This transcript was mostly present in brain at
approximately 3–6% of the Pkd2 transcript level. The expression
pattern of those alternatively spliced variants is genetically conserved
from mouse to dog to human. Although it is speculated that these
variants are important for PKD2 gene regulation their functional
signiﬁcance is uncertain.
Alternatively spliced transcripts also are well documented in the
single-copy mouse and rat PKD1 genes. In mouse, alternative splicing
of exons 12 and 13 generates several splicing variants leading to
a predicted protein that would be secreted. Those forms are pre-
dominantly found in newborn murine brain but not in kidney [68].
Xu et al. found a similarly complex pattern of exon 12 splicing in rat
brain but not other rat tissues [69]. They also identiﬁed a splicing
variant lacking exon 31 in a variety of rat and mouse tissues but not in
humans. Studies of alternative splicing for the human PKD1 gene was
complicated by the presence of transcribed pseudogenes. Alternative
splicing of exons 16 and 24, predicted to code a truncated form of PC1,
was reported for human PKD1 [10,13]; however, their origin (PKD1 or
the associated pseudogenes) has not been determined. Furthermore,
these two splice variants could not be found in mouse and rat tissues.
Recently, Tan et al. have identiﬁed and characterized a novel missense
mutation in PKD2 leading to stable accumulation of transcript with
aberrantly spliced exon 6, predicted to encode truncated protein with
null function. This particular splice variant was also present, but at
signiﬁcantly lower amounts, in peripheral blood lymphocytes from
normal individuals andADPKDpatientswith other PKD genemutations.
The expression pattern of this PKD2 gene variant in kidney and other
tissues or its biological signiﬁcance is currently unknown [70].6. MicroRNA in ADPKD
MicroRNAs (miRNAs) are short, noncoding, single-stranded RNAs
of about 22 nucleotides (nt) in length processed from longer (80–85 nt)
precursor hairpins by the RNase III enzyme [71]. Fig. 3 shows the
main steps in miRNA biogenesis and action. miRNAs have important
regulatory roles in a broad range of biological processes, including
the pathogenesis of malignancy, cellular differentiation, proliferation,
apoptosis and gene regulation [72]. To date, the list of miRNAs
consists of more than 10,000 entries on the miRBase (release 14,
http://www.mirbase.org/)[73], with 721 human miRNAs accounting
for approximately 2% of all known human genes. In silico analysis
indicates that more than 60% of human protein-coding genes are
predicted to be regulated by miRNAs [74]. A single miRNA has the
potential to regulate many mRNA transcripts and a single mRNA can
serve as a target of multiple miRNAs [75].
miRNAs can induce ADPKD cytogenesis by affecting numerous
target genes involved in cell proliferation as well as by directly
regulating PKD gene expression. Lee et al. provided the ﬁrst evidence,
using microarrays, to show that miRNAs are involved in the path-
ogenesis of polycystic liver disease by analyzing the microRNA pro-
ﬁle of cholangiocytes from rats with polycystic kidneys (PCK), an
established model for autosomal recessive polycystic kidney disease
(ARPKD) [76]. They found numerous miRNAs that were differentially
expressed or present in the control cell line, but not in the PCK
cholangiocyte cell line (PCK-CCL). Further investigation demonstrated
that miR-15a levels, a miRNA that was downregulated in PCK-CCL by
37-fold, were signiﬁcantly reduced in liver specimens from patients
with ADPKD, ARPKD and congenital hepatic ﬁbrosis (CHF) [76].
Reduced expression of miR-15a in the cystic tissues was associated
with up-regulation of its target, the cell cycle regulator Cdc25A. Over-
expression of miR-15a in PCK-CCL decreased Cdc25A level and
Fig. 2. PKD1 gene structure and distribution of genetic variants. Upper panels show PKD1 gene andmRNA structure. Lower panels show the spectrum and distribution of PKD1 genetic
variants, grouped by mutation type, according to their relative position on mRNA. Deﬁnite pathogenic mutations are colored red; other changes are colored green.
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rat cholangiocytes increased Cdc25A expression, accelerating cell
proliferation, and promoting cyst growth. Using similar microarrayFig. 3. A schematic diagram ofmiRNA biogenesis and action. Most primarymiRNAs (pri-miRN
the nucleus into 50- to 80-base pre-miRNA by the Drosha endonuclease complex. The stem-
further processed by Dicer complex into duplexes that contain the 20–24 nucleotide long
Silencing Complex (RISC) to form miRNA-RISC assembly. In mammalian cell, miRNA in the
paring, repressing protein translation.strategy and PKD/mhm (cy/+) rats, an accepted rat model for human
ADPKD [77], Pandey et al. [78] have identiﬁed a single miRNA, miR-21
which was up-regulated in kidney from PKD/mhm (cy/+) comparedAs) are transcribed from genomic DNA by RNA polymerase II. Pri-miRNAs are cleaved in
loop structured pre-miRNAs are then transported into the cytoplasm by exportin-5 and
mature miRNA. The functional strand of this duplex is loaded into the RNA-induced
mi-RISC complex binds to their target mRNAs through imperfect complementary base-
1207Y.-C. Tan et al. / Biochimica et Biophysica Acta 1812 (2011) 1202–1212to controls. Several othermiRNAs, such asmiR-31, miR-196a andmiR-
125 were consistently down regulated in both studies despite the
different animal/disease model and different tissue type. Complete
analysis of miRNA expression in human polycystic kidney tissue has
not yet been performed andwill likely provide new insights regarding
the role of miRNAs in ADPKD development.
Another possible role of miRNAs involving ADPKD might be the
direct regulation of PKD gene expression. In silico analysis by Target Scan
(http://www.targetscan.org/) identiﬁed several putativemiRNAbinding
sites in the3' UTR of both PKDgenes (UCSC genomebrowser, hg18, 2006
Assembly, http://www.genome.ucsc.edu/cgi-bin/hgGateway). As
shown in Fig. 4, PKD1 has two putative binding sites: region 1 predicted
to bind miR-200b/c and miR-429, while region 2 is expected to bind
miR17-5p, miR-20, miR-93, miR-106 and miR-519. The 3' UTR of PKD2
has three predicted miRNA binding sites: region 1 which has the same
binding properties as PKD1 region 2; region 2 that can bindmiR-539 and
region3 canbindmiR-194.Hurteanet al. establishedan in vivo systemto
investigate the endogenous interaction between miR-200c and its
predicted targets [79], but there was no effect on PKD1 gene expression.
Sun et al. established an in vitro system to investigate the interaction
between miR-17 and its putative target PKD2 [80], demonstrating that
miR-17 can directly bind the PKD2 3' UTR. Over-expression of miR-17 in
HEK293T (human embryonic kidney cell line) can decrease PKD2
protein level but notmRNA levels. They also provided evidence that thisFig. 4. Putative miRNA binding sites predicted by TargetScan at the 3' UTR of the PKD genes
upper panel. The two predicted miRNA binding sites are denoted with dark green rectangle
from the stop codon. PKD1 mRNA sequence from human, mouse, rat, dog and chicken are sh
three putative miRNA binding sites on PKD2 gene are shown. This graph was generated by
with some modiﬁcations (http://genome.ucsc.edu/cgi-bin/hgGateway).interaction had a role in cell proliferation. Tran et al. [81] further
demonstrated that a RNA-binding protein Bicaudal C (Bicc1), an
important regulator of embryonic development, modulated the ex-
pression of PC2 by antagonizing the repressive activity of miR-17
on PKD2 mRNA. They proposed that the PKD phenotype of Bicc1
knockout mice could be explained by the deregulation of this miRNA-
based translational controlmechanism.Although theﬁrst report failed to
establish the correlation between miR-200c and PKD1, it did not
disprove the notion that PKD1 is still a target for miR-200C,
by affecting PKD1 protein levels rather than mRNA level, as was
demonstrated for PKD2. These observations are consistent with
the current working hypothesis that miRNAs mainly act through
suppressing protein translation rather than mediating mRNA degrada-
tion. Clearly, further work is needed to better understand the role of
miRNAs in regulating PKD gene expression in vivo and their potential
role in cystogenesis.
It is worth noting the identiﬁcation of a microRNA gene lying
within intron 45 of PKD1: miR-1225, belonging to the Mirtron family.
Mirtrons are short introns with hairpin potential that can be spliced
and debranched into pre-microRNA hairpins without the canonical
Drosha cleavage step. Those pre-miRNAs then enter the normal
miRNA biogenesis pathway, after being cleaved by Dicer, becoming
the mature miRNAs. Pathogenic mutations in this intron affecting
the splicing of exon 45 have been reported [82,83]. The function of. (A) 3' UTR of PKD1 gene and its relative position on chromosome 16 is shown on the
. Lower panels show the details of those sites. The number indicates the distance in bp
own and the conserved nucleotides are indicated in green on the bottom line. (B) The
using UCSC genome browser, hg18, 2006 Assembly, with TargetScan miRNA sites track
1208 Y.-C. Tan et al. / Biochimica et Biophysica Acta 1812 (2011) 1202–1212this mirtron is currently unknown, but it is quite possible that
mutations affecting its function will inﬂuence disease development or
progression.7. Molecular diagnosis of ADPKD
The diagnosis of ADPKD is determined by renal imaging tech-
niques coupled with an age-speciﬁc renal phenotype. This is based
upon the number of cysts identiﬁed by renal ultrasonography
together with a 50% risk of inheritance, determined by a positive
family history of ADPKD [84] [85]. The diagnosis often is ambiguous
in young patients, where renal sonography may not be conclusive or
when the family history is unknown. This is a signiﬁcant issue when
renal donation is being considered before age 30 years, when the
sensitivity of these criteria is only 67% in patients with a PKD2
mutation [86]. Genetic testing of PKD1 and PKD2 can be useful for
diagnosis and prognosis of ADPKD, particularly for asymptomatic
individuals, or those without a family history [87]. Recently, Huang
et al. proposed an algorithm that incorporates the use of DNA testing
and imaging for donors with a positive family history of ADPKD [88].
However, this need to be further validated, given the different
sensitivity of each renal imaging methods (i.e., ultrasonography, MRI,
CT) and the high cost of PKD genotyping by a commercial laboratory
(i.e., ~$5000 per test) [87].
Two methods are available for genetic testing of ADPKD: DNA
linkage analysis and gene-based mutation screening. Linkage analysis
employs highly informative microsatellite markers ﬂanking PKD1 and
PKD2 and is suitable in fewer than 50% of families because of certain
constraints such as the lack of willingness and availability of sufﬁcient
affected family members [89]. Once linkage analysis has been per-
formed, haplotype reconstruction can be used to predict the disease
status of other members of this family. This method is currently
seldom used, but may be considered in situations such as prenatal
testing in which the mutation is unknown. Linkage analysis also is
considered the method of choice for pre-implantation genetic diag-
nosis (PGD), where the typing of several markers is recommended
to ensure against confounders such as allele dropout (see below),
which can occurs when amplifying very low amounts of DNA and/or
highly polymorphic genes such as PKD1 [90] [12]. Molecular testing by
gene-based mutation screening has currently become the method of
choice; however, this method is technically challenging because of
the large size and duplicated region of PKD1 and the marked allelic
heterogeneity of the disease-associated mutations, the vast majority
of which are rare. Analyzing the PKD2 gene and the PKD1 single-copy
region is straightforward. By contrast, analysis of the duplicated 5'
region of PKD1, which is highly homologous to PKD1 pseudogenes, is
more complex, requiring PCR primers anchored in the single-copy
DNA or mismatched with the homolog genes sequences.
Mutation screening of PKD genes can be performed using either
DNA or mRNA. Rossetti et al. developed the ﬁrst whole gene analysis
strategy for PKD1, combining themRNA based Protein Truncation Test
(PTT) and DNA-based direct sequencing of the entire gene-sequence,
by employing long-range PCR to speciﬁcally amplify the duplicated
exon 1 to exon 33 regions [63]. Prior to the development of these
methods, mutation analyses for ADPKD focused primarily on the PKD2
gene and the 3' single-copy region of PKD1.
Complete gene sequencing remains the gold standard formutation
analysis, but it is extremely expensive and time-consuming. Direct
DNA sequencing is employed as the screeningmethod for commercial
genetic testing of ADPKD. Garcia-Gonzalez et al. evaluated the clinical
utility of this commercially available test by analyzing a cohort of 82
ADPKD patients [91]. Deﬁnite pathogenic mutations were detected in
42% of the patients and the maximal mutation detection rate was 78%,
after including likely pathogenic missense mutations, in-frame
insertion/deletion and atypical splice mutations [91].Several mutation screeningmethods were also developed to lower
testing costs and minimize turnaround time. Denaturing gradient gel
electrophoresis (DGGE), a traditional gel-based heteroduplex analysis
method, has been successfully used to screen both the single-copy
and the duplicated regions of the PKD1 gene [92,93]. Single-strand
conformation polymorphism (SSCP) also has been employed for
detecting PKD gene mutations [94] [95] [96] [97]. However, the latter
method only detected about 30-40% of the deﬁnite mutations with an
overall mutation detection rate of 70%. Rossetti et al. [98] have
developed a DNA high-pressure liquid chromatography (DHPLC)
screening method for both PKD genes, and validated the method in a
relatively large cohort. This method proved to be more sensitive
compared to the other methods with a maximal mutation detection
rate of 76% and a rate of 64% for deﬁnite mutations. Tan et al. have
further improved the utility of DHPLC for genetic testing by using Cel I
endonuclease (SURVEYOR® nuclease, Transgenomic Inc.) and the
Transgenomic WAVE® Nucleic Acid High Sensitivity Fragment
Analysis System for mutation screening of PKD genes (Fig. 5) [62].
Using this method, they have analyzed 25 patients from the Rogosin
Institute ADPKD Data Repository and compared the results to
complete DNA sequencing performed by a commercial reference
laboratory. This commercial reference laboratory has exclusive license
for the PKD1 and PKD2 patents and is the sole provider of clinical
ADPKD testing in the United States. The SURVEYOR-WAVE-Sequenc-
ing method was found to be 100% sensitive, with a detection rate of
64% for deﬁnite pathogenic mutations. Moreover, two nonsense
changes, p.Q2669X and p.E3871X, reported by the reference labora-
tory as homozygous mutations were determined to be heterozygous
by SURVEYOR and subsequent conﬁrmatory sequence analysis [62].
The incorrect designation of homozygosity for the nonsense mutation
reported by the reference laboratory was probably caused by allele
dropout during PCR ampliﬁcation. Allele dropout or pseudo-homo-
zygosity has been well documented and is likely due to the presence
of a SNP in the primer binding region of one of the two alleles
resulting in lower or complete lack of ampliﬁcation of one allele [99].
Moreover, homozygosity or compound heterozygosity of PKD1 or
PKD2 mutations in PKD are embryonic lethal phenotypes [34] [35]
[29]. Therefore, it is unlikely that either of these subjects has a
homozygous germ line mutation. Allele dropout during PCR ampli-
ﬁcation due to a SNP in the primer-binding region is possible with any
PCR ampliﬁcation method, warranting further investigation before
clinical reporting.
Large DNA rearrangements also were reported to be involved in
ADPKD causation, but their detection is complicated by the presence
of the PKD1 pseudogenes. Field inversion gel electrophoresis (FIGE),
followed by Southern blot analysis, has been traditionally employed
to investigate large deletions in PKD1, which reportedly account for
approximately 2–3% of all PKD1mutations [100]. Recently, amultiplex
ligation dependent probe assay (MLPA) was developed for detecting
large genomic rearrangements in PKD genes [101,102]. Using this
method, Consugar et al. were able to conﬁrm the presence of deletions
in a cohort of 25 patients and found that 4% of patients (31% of
the sequence-determined mutation negative cases) in the CRISP
had gross rearrangements in PKD genes [102]. Interestingly, these
rearrangements include PKD1 deletions extending 100 kb 5' to the
gene, removing 10 additional genes without apparent additional
phenotypic consequences. Deletions extending 3' to PKD1 also disrupt
TSC2, resulting in a contiguous gene deletion syndrome, which has a
distinct phenotype consisting of tuberous sclerosis and severe clinical
manifestations of ADPKD [44,102].
In the future, next generation sequencing methods have the
potential to dramatically improve genetic testing for PKD genes by
allowing simultaneous detection of point mutations and copy number
variations in a single test. Accordingly, these methods would increase
the mutation detection rate and signiﬁcantly reduce testing costs and
turnaround time.
Fig. 5. SURVEYOR-WAVE-Sequencing analysis of PKD1 exon 46A and PKD2 exon 1A. Corresponding exons in PKD1 and PKD2were ampliﬁed using patients' peripheral blood lymphocytes DNA.
PCR fragmentswere subjected toSURVEYORnucleasedigestion followedbyWAVE-HSanalysis, using thenon-denaturing sizingapplication. Shownonthe left are thechromatographsgenerated
byWAVE-HSanalysis,withall fourpatientDNAsproducingdigestionproducts (*/#)notobserved for thecontrolDNA. Shownonthe right are thecorresponding sequencing results.Upperpanel:
two patient samples demonstrating distinct digestion proﬁles corresponding to two different single gene variations within PKD1 exon 46A: c.12460TNG (p.F4154V) and c.12627TNC (p. =),
respectively. Lower panel: PCRproducts digestion proﬁles for the twopatients revealed threedistinct PKD2 exon1Avariants,withpatient 3 containing twovariants: c.196_199dup (p.P67fsX26)
plus c.83GNC (p.R28P) and c.83GNC (p.R28P), respectively. The dashed line represents a size marker of 50 bp.
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Analysis of variants of uncertain signiﬁcance (VUS) has become an
important component of molecular diagnosis of ADPKD. Determining
the pathogenicity of deleterious changes, such as frame-shift, non-
sense, typical splicing or large rearrangement can often be accom-
plished with certainty; however, this is not the case for genetic
variations that are not predicted to truncate the protein. This latter
group of genetic changes, which often cannot be readily classiﬁed,
include synonymous and non-synonymous variants, and small in-
frame deletions. Due to the high level of genetic variation found in
PKD1 gene (10.1 variants per patient, ranging from 0 to 55), analyzing
the pathogenic potential of VUS plays an important role in molecular
diagnosis of ADPKD [91].
Computational analysis of VUS includes evaluation of interspecies
variations and chemical differences of resulting amino acid substitu-
tions. Rossetti et al. developed a methods based on Grantham Matrix
Score (GMS) to predict the pathogenic effect of non-synonymous
changes for ADPKD [60]. The GMS is based on a score system call,
Grantham difference, which describes the difference in side-chain
atomic composition, polarity and volume between two amino acids
[103]. The GMS has two scores: Grantham variation (GV) which
calculate the range of variation present at each position in the multiple
sequence alignment (MSA) of protein orthologs throughout evolution,
and Grantham distance (GD) that measures the distance of a missense
substitution from the edge of the range of variation. The scores from
these two variables are combined to provider a classiﬁer to estimate thegenetic risk [104]. One critical step in assigning GMS is generating the
MSA. Rossetti et al. generated an MSA of PC1 orthologs from ﬁsh to
human in their study [60]. The Grantham Matrix Score can be freely
calculated online using the Align-GVGD application (http://www.
agvgd.iarc.fr/) [104] [105]. Our laboratory integrates the results of
Align-GVGD with that of two other analysis programs: SIFT (http://
www.sift.jcvi.org/) [106] [107] and PolyPhen (http://www.genetics.
bwh.harvard.edu/pph/) [108] [109]. SIFT and PolyPhen are based on
similar principles such as GMS, but employ different analysis criteria.
Both applications can search online databases and generate MSA [62].
Several other programs that are based on different prediction
principles can predict the potential of mutations to alter splicing. A few
of these applications include Splice Site Prediction by Neural Network
(http://www.fruitﬂy.org/seq_tools/splice.html) [110], ESEﬁnder
(http://www.rulai.cshl.edu/cgi-bin/tools/ESE3/eseﬁnder.cgi) [111] and
Human Splicing Finder (http://www.umd.be/HSF/) [112]. The predic-
tion results of atypical splicing can be further conﬁrmed by RT-PCR
analysis, given the patient's RNA is available. However, studies to assess
the functional impact of missense mutations, particularly for PKD1, are
somewhat more difﬁcult, particularly because of the large size and
uncertain functions of the polycystins. For the CRISP cohort, 38 of 99
(38%) missense changes were predicted to be pathogenic, with 35 in
PKD1 and 3 in PKD2 [60]. For the Rogosin study, 6 out of 26 (23%)
missense changes were predicted to be pathogenic, all of whichwere in
PKD1 [62]. Garcia-Gonzalez et al. found17of 62 (27%)missense changes
to be probably pathogenic when screening a cohort of 82 ADPKD
patients; all variants were located in PKD1 [91]. Using these methods,
1210 Y.-C. Tan et al. / Biochimica et Biophysica Acta 1812 (2011) 1202–1212the detection rate of ‘Probably Pathogenic’ mutations can be increased
to over 85% [60,62].
In ~10% of individuals with clinical ADPKD, no mutation in either
PKD1 or PKD2 is detected. This may be due to missed mutations such
as deep intronic changes that affect splicing or gene promoter changes
not detected by current exon-based screening methods [113].
Alternatively, it is possible that the disease in these patients is caused
by a third gene, as several families unlinked to PKD1 or PKD2 have
been described [114] [115].
9. Summary
In this chapter, we have summarized information that is important
for understanding themultiple geneticmechanisms underlying ADPKD.
Completion of the Human Genome Project, the rapid development of
molecular genetic tools, improved bioinformatics applications, and the
establishment of strong ADPKD databases have greatly aided with
mutation identiﬁcation and characterization. ADPKD genetic testing is
now readily available, in some instances becoming themethod of choice
for ADPKD diagnosis. Better understanding of genotype/phenotype
correlation as well as microRNA proﬁling will further enhance the
development of novel diagnostic and prognostic biomarkers as well as
prompting personalized patient management. This process will likely
accelerate as effective therapies become available. The biggest chal-
lenges facing this ﬁeld include the evaluation of new testing technol-
ogies for clinical diagnosis of ADPKD, incorporation of new approaches
for data analysis and management, and changing regulations standards
for clinical laboratories.
Acknowledgment
We thank Alber Michaeel and Sylvia Boctor for helping preparing
the ﬁgures. We also thank Dr. Debra G.B. Leonard for critical review
of the manuscript. We thank the curators of the ADPKD Mutation
Database at Mayo Clinic, MN, for the permission to use mutation
information for this manuscript. The project described was supported
by Grant Award Number UL1RR024143 from the National Center for
Research Resources (NCRR), a component of the National Institutes of
Health (NIH) and NIH Roadmap for Medical Research, and its contents
are solely the responsibility of the authors and do not necessarily
represent the ofﬁcial view of NCRR or NIH.
References
[1] O.Z. Dalgaard, Bilateral polycystic disease of the kidneys; a follow-up of 284
patients and their families, Dan. Med. Bull. 4 (1957) 128–133.
[2] C.G. Iglesias, V.E. Torres, K.P. Offord, K.E. Holley, C.M. Beard, L.T. Kurland,
Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota:
1935–1980, Am. J. Kidney Dis. 2 (1983) 630–639.
[3] D.J. Peters, L.A. Sandkuijl, Genetic heterogeneity of polycystic kidney disease in
Europe, Contrib. Nephrol. 97 (1992) 128–139.
[4] V.E. Torres, P.C. Harris, Autosomal dominant polycystic kidney disease: the last 3
years, Kidney Int. 76 (2009) 149–168.
[5] W.E. Braun, Autosomal dominant polycystic kidney disease: emerging concepts
of pathogenesis and new treatments, Cleve. Clin. J. Med. 76 (2009) 97–104.
[6] P.C. Harris, V.E. Torres, Polycystic kidney disease, Annu. Rev.Med. 60 (2009) 321–337.
[7] S. Rossetti, S. Burton, L. Strmecki, G.R. Pond, J.L. SanMillan, K. Zerres, T.M. Barratt,
S. Ozen, V.E. Torres, E.J. Bergstralh, C.G. Winearls, P.C. Harris, The position of the
polycystic kidney disease 1 (PKD1) genemutation correlates with the severity of
renal disease, J. Am. Soc. Nephrol. 13 (2002) 1230–1237.
[8] C.L. Kelleher, K.K. McFann, A.M. Johnson, R.W. Schrier, Characteristics of hypertension
in young adults with autosomal dominant polycystic kidney disease compared with
the general U.S. population, Am. J. Hypertens. 17 (2004) 1029–1034.
[9] V.E. Torres, P.C. Harris, Y. Pirson, Autosomal dominant polycystic kidney disease,
Lancet 369 (2007) 1287–1301.
[10] J. Hughes, C.J. Ward, B. Peral, R. Aspinwall, K. Clark, J.L. San Millan, V. Gamble, P.C.
Harris, The polycystic kidney disease 1 (PKD1) gene encodes a novel protein
with multiple cell recognition domains, Nat. Genet. 10 (1995) 151–160.
[11] T. Mochizuki, G. Wu, T. Hayashi, S.L. Xenophontos, B. Veldhuisen, J.J. Saris, D.M.
Reynolds, Y. Cai, P.A. Gabow, A. Pierides, W.J. Kimberling, M.H. Breuning, C.C.
Deltas, D.J. Peters, S. Somlo, PKD2, a gene for polycystic kidney disease that
encodes an integral membrane protein, Science 272 (1996) 1339–1342.[12] P.C. Harris, S. Rossetti, Molecular diagnostics for autosomal dominant polycystic
kidney disease, Nat. Rev. Nephrol. (2010).
[13] T.I.P.K.D. Consortium, Polycystic kidney disease: the complete structure of the
PKD1 gene and its protein. The International Polycystic Kidney Disease
Consortium, Cell 81 (1995) 289–298.
[14] E. Dicks, P. Ravani, D. Langman, W.S. Davidson, Y. Pei, P.S. Parfrey, Incident renal
events and risk factors in autosomal dominant polycystic kidney disease: a
population and family-based cohort followed for 22 years, Clin. J. Am. Soc.
Nephrol. 1 (2006) 710–717.
[15] B. Reed, K. McFann, W.J. Kimberling, Y. Pei, P.A. Gabow, K. Christopher, E.
Petersen, C. Kelleher, P.R. Fain, A. Johnson, R.W. Schrier, Presence of de novo
mutations in autosomal dominant polycystic kidney disease patients without
family history, Am. J. Kidney Dis. 52 (2008) 1042–1050.
[16] F. Qian, A. Boletta, A.K. Bhunia, H. Xu, L. Liu, A.K. Ahrabi, T.J. Watnick, F. Zhou, G.G.
Germino, Cleavage of polycystin-1 requires the receptor for egg jelly domain and is
disrupted by human autosomal-dominant polycystic kidney disease 1-associated
mutations, Proc. Natl Acad. Sci. USA 99 (2002) 16981–16986.
[17] M. Bycroft, A. Bateman, J. Clarke, S.J. Hamill, R. Sandford, R.L. Thomas, C. Chothia,
The structure of a PKD domain from polycystin-1: implications for polycystic
kidney disease, EMBO J. 18 (1999) 297–305.
[18] H.J. Gunaratne, G.W. Moy, M. Kinukawa, S. Miyata, S.A. Mah, V.D. Vacquier, The
10 sea urchin receptor for egg jelly proteins (SpREJ) are members of the
polycystic kidney disease-1 (PKD1) family, BMC Genomics 8 (2007) 235.
[19] V. Chauvet, X. Tian, H. Husson, D.H. Grimm, T.Wang, T. Hiesberger, P. Igarashi, A.M.
Bennett, O. Ibraghimov-Beskrovnaya, S. Somlo, M.J. Caplan, Mechanical stimuli
induce cleavage and nuclear translocation of the polycystin-1 C terminus, J. Clin.
Invest. 114 (2004) 1433–1443.
[20] R. Sandford, B. Sgotto, S. Aparicio, S. Brenner, M. Vaudin, R.K. Wilson, S. Chissoe,
K. Pepin, A. Bateman, C. Chothia, J. Hughes, P. Harris, Comparative analysis of
the polycystic kidney disease 1 (PKD1) gene reveals an integral membrane
glycoprotein with multiple evolutionary conserved domains, Hum. Mol. Genet. 6
(1997) 1483–1489.
[21] K. Hanaoka, F. Qian, A. Boletta, A.K. Bhunia, K. Piontek, L. Tsiokas, V.P. Sukhatme,
W.B. Guggino, G.G. Germino, Co-assembly of polycystin-1 and −2 produces
unique cation-permeable currents, Nature 408 (2000) 990–994.
[22] A. Celic, E.T. Petri, B. Demeler, B.E. Ehrlich, T.J. Boggon, Domain mapping of the
polycystin-2 C-terminal tail using de novo molecular modeling and biophysical
analysis, J. Biol. Chem. 283 (2008) 28305–28312.
[23] B.K. Yoder, X.Y. Hou, L.M. Guay-Woodford, The polycystic kidney disease
proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal
cilia, J. Am. Soc. Nephrol. 13 (2002) 2508–2516.
[24] F. Qian, F.J. Germino, Y. Cai, X. Zhang, S. Somlo, G.G. Germino, PKD1 interacts with
PKD2 through a probable coiled-coil domain, Nat. Genet. 16 (1997) 179–183.
[25] S.H. Low, S. Vasanth, C.H. Larson, S. Mukherjee, N. Sharma, M.T. Kinter, M.E. Kane,
T. Obara, T. Weimbs, Polycystin-1, STAT6, and P100 function in a pathway that
transduces ciliary mechanosensation and is activated in polycystic kidney
disease, Dev. Cell 10 (2006) 57–69.
[26] S.M. Nauli, F.J. Alenghat, Y. Luo, E. Williams, P. Vassilev, X. Li, A.E. Elia, W. Lu,
E.M. Brown, S.J. Quinn, D.E. Ingber, J. Zhou, Polycystins 1 and 2 mediate
mechanosensation in the primary cilium of kidney cells, Nat. Genet. 33
(2003) 129–137.
[27] T. Yamaguchi, D.P. Wallace, B.S. Magenheimer, S.J. Hempson, J.J. Grantham, J.P.
Calvet, Calcium restriction allows cAMP activation of the B-Raf/ERK pathway,
switching cells to a cAMP-dependent growth-stimulated phenotype, J. Biol.
Chem. 279 (2004) 40419–40430.
[28] J.J. Grantham, Clinical practice Autosomal dominant polycystic kidney disease, N
Engl J Med 359 (2008) 1477–1485.
[29] G.Wu,X. Tian, S.Nishimura,G.S.Markowitz, V.D'Agati, J.H. Park, L. Yao, L. Li, L. Geng,
H. Zhao, W. Edelmann, S. Somlo, Trans-heterozygous Pkd1 and Pkd2 mutations
modify expression of polycystic kidney disease, Hum. Mol. Genet. 11 (2002)
1845–1854.
[30] J.L. Brasier, E.P. Henske, Loss of the polycystic kidney disease (PKD1) region of
chromosome 16p13 in renal cyst cells supports a loss-of-function model for cyst
pathogenesis, J. Clin. Invest. 99 (1997) 194–199.
[31] M.A. Arnaout, Molecular genetics and pathogenesis of autosomal dominant
polycystic kidney disease, Annu. Rev. Med. 52 (2001) 93–123.
[32] Y. Pei, A "two-hit" model of cystogenesis in autosomal dominant polycystic
kidney disease? Trends Mol. Med. 7 (2001) 151–156.
[33] Y. Pei, A.D. Paterson, K.R. Wang, N. He, D. Hefferton, T. Watnick, G.G. Germino, P.
Parfrey, S. Somlo, P. St George-Hyslop, Bilineal disease and trans-heterozygotes
in autosomal dominant polycystic kidney disease, Am. J. Hum. Genet. 68 (2001)
355–363.
[34] W. Lu, X. Shen, A. Pavlova, M. Lakkis, C.J. Ward, L. Pritchard, P.C. Harris, D.R.
Genest, A.R. Perez-Atayde, J. Zhou, Comparison of Pkd1-targeted mutants reveals
that loss of polycystin-1 causes cystogenesis and bone defects, Hum. Mol. Genet.
10 (2001) 2385–2396.
[35] S. Muto, A. Aiba, Y. Saito, K. Nakao, K. Nakamura, K. Tomita, T. Kitamura, M.
Kurabayashi, R. Nagai, E. Higashihara, P.C. Harris, M. Katsuki, S. Horie,
Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1
mutant, Hum. Mol. Genet. 11 (2002) 1731–1742.
[36] W. Lu, X. Fan, N. Basora, H. Babakhanlou, T. Law, N. Rifai, P.C. Harris, A.R. Perez-
Atayde, H.G. Rennke, J. Zhou, Late onset of renal and hepatic cysts in Pkd1-
targeted heterozygotes, Nat. Genet. 21 (1999) 160–161.
[37] K. Piontek, L.F. Menezes, M.A. Garcia-Gonzalez, D.L. Huso, G.G. Germino, A critical
developmental switch deﬁnes the kinetics of kidney cyst formation after loss of
Pkd1, Nat. Med. 13 (2007) 1490–1495.
1211Y.-C. Tan et al. / Biochimica et Biophysica Acta 1812 (2011) 1202–1212[38] I.S. Lantinga-van Leeuwen, J.G. Dauwerse, H.J. Baelde, W.N. Leonhard, A. van de
Wal, C.J. Ward, S. Verbeek, M.C. Deruiter, M.H. Breuning, E. de Heer, D.J. Peters,
Lowering of Pkd1 expression is sufﬁcient to cause polycystic kidney disease,
Hum. Mol. Genet. 13 (2004) 3069–3077.
[39] S.T. Jiang, Y.Y. Chiou, E. Wang, H.K. Lin, Y.T. Lin, Y.C. Chi, C.K. Wang, M.J. Tang, H. Li,
Deﬁning a link with autosomal-dominant polycystic kidney disease in mice with
congenitally low expression of Pkd1, Am. J. Pathol. 168 (2006) 205–220.
[40] C. Thivierge, A. Kurbegovic, M. Couillard, R. Guillaume, O. Cote, M. Trudel,
Overexpression of PKD1 causes polycystic kidney disease, Mol. Cell. Biol. 26
(2006) 1538–1548.
[41] E.Y. Park, Y.H. Sung, M.H. Yang, J.Y. Noh, S.Y. Park, T.Y. Lee, Y.J. Yook, K.H. Yoo, K.J.
Roh, I. Kim, Y.H. Hwang, G.T. Oh, J.K. Seong, C. Ahn, H.W. Lee, J.H. Park, Cyst
formation in kidney via B-Raf signaling in the PKD2 transgenic mice, J. Biol.
Chem. 284 (2009) 7214–7222.
[42] S. Burtey, M. Riera, E. Ribe, P. Pennekamp, E. Passage, R. Rance, B. Dworniczak, M.
Fontes, Overexpression of PKD2 in the mouse is associated with renal
tubulopathy, Nephrol. Dial. Transplant. 23 (2008) 1157–1165.
[43] A.R. Gallagher, S. Hoffmann, N. Brown, A. Cedzich, S. Meruvu, D. Podlich, Y. Feng, V.
Konecke, U. de Vries, H.P. Hammes, N. Gretz, R. Witzgall, A truncated polycystin-2
protein causespolycystic kidneydisease and retinaldegeneration in transgenic rats,
J. Am. Soc. Nephrol. 17 (2006) 2719–2730.
[44] P.C. Harris, What is the role of somatic mutation in autosomal dominant
polycystic kidney disease? J. Am. Soc. Nephrol. 21 (2010) 1073–1076.
[45] M. Koptides, R. Mean, K. Demetriou, A. Pierides, C.C. Deltas, Genetic evidence for
a trans-heterozygous model for cystogenesis in autosomal dominant polycystic
kidney disease, Hum. Mol. Genet. 9 (2000) 447–452.
[46] N. Hateboer, M.A. v Dijk, N. Bogdanova, E. Coto, A.K. Saggar-Malik, J.L. San Millan,
R. Torra, M. Breuning, D. Ravine, Comparison of phenotypes of polycystic kidney
disease types 1 and 2. European PKD1-PKD2 Study Group, Lancet 353 (1999)
103–107.
[47] P.C. Harris, K.T. Bae, S. Rossetti, V.E. Torres, J.J. Grantham, A.B. Chapman, L.M.
Guay-Woodford, B.F. King, L.H. Wetzel, D.A. Baumgarten, P.J. Kenney, M.
Consugar, S. Klahr, W.M. Bennett, C.M. Meyers, Q.J. Zhang, P.A. Thompson, F.
Zhu, J.P. Miller, Cyst number but not the rate of cystic growth is associated with
the mutated gene in autosomal dominant polycystic kidney disease, J. Am. Soc.
Nephrol. 17 (2006) 3013–3019.
[48] P.C. Harris, 2008, Homer W Smith Award insights into pathogenesis polycystic
kidney disease gene discovery J Am Soc Nephrol 20 (2009) 1188–1198.
[49] R. Magistroni, N. He, K. Wang, R. Andrew, A. Johnson, P. Gabow, E. Dicks, P.
Parfrey, R. Torra, J.L. San-Millan, E. Coto, M. Van Dijk, M. Breuning, D. Peters, N.
Bogdanova, G. Ligabue, A. Albertazzi, N. Hateboer, K. Demetriou, A. Pierides, C.
Deltas, P. St George-Hyslop, D. Ravine, Y. Pei, Genotype-renal function
correlation in type 2 autosomal dominant polycystic kidney disease, J. Am. Soc.
Nephrol. 14 (2003) 1164–1174.
[50] S. Rossetti, D. Chauveau, V. Kubly, J.M. Slezak, A.K. Saggar-Malik, Y. Pei, A.C. Ong,
F. Stewart, M.L. Watson, E.J. Bergstralh, C.G. Winearls, V.E. Torres, P.C. Harris,
Association of mutation position in polycystic kidney disease 1 (PKD1) gene and
development of a vascular phenotype, Lancet 361 (2003) 2196–2201.
[51] S. Rossetti, V.J. Kubly, M.B. Consugar, K. Hopp, S. Roy, S.W. Horsley, D. Chauveau,
L. Rees, T.M. Barratt, W.G. van't Hoff, W.P. Niaudet, V.E. Torres, P.C. Harris,
Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst
initiation in polycystic kidney disease, Kidney Int. 75 (2009) 848–855.
[52] M. Vujic, C.M. Heyer, E. Ars, K. Hopp, A. Markoff, C. Orndal, B. Rudenhed, S.H.
Nasr, V.E. Torres, R. Torra, N. Bogdanova, P.C. Harris, Incompletely penetrant
PKD1 alleles mimic the renal manifestations of ARPKD, J. Am. Soc. Nephrol. 21
(2010) 1097–1102.
[53] S. Geberth, E. Ritz, M. Zeier, E. Stier, Anticipation of age at renal death in autosomal
dominant polycystic kidney disease (ADPKD)? Nephrol. Dial. Transplant. 10 (1995)
1603–1606.
[54] B. Peral, V. Gamble, J.L. San Millan, C. Strong, J. Sloane-Stanley, F. Moreno, P.C.
Harris, Splicing mutations of the polycystic kidney disease 1 (PKD1) gene
induced by intronic deletion, Hum. Mol. Genet. 4 (1995) 569–574.
[55] A. Persu, M. Duyme, Y. Pirson, X.M. Lens, T. Messiaen, M.H. Breuning, D. Chauveau, M.
Levy, J.P. Grunfeld, O.Devuyst, Comparison between siblings and twins supports a role
for modiﬁer genes in ADPKD, Kidney Int. 66 (2004) 2132–2136.
[56] P.R. Fain, K.K. McFann, M.R. Taylor, M. Tison, A.M. Johnson, B. Reed, R.W. Schrier,
Modiﬁer genes play a signiﬁcant role in the phenotypic expression of PKD1,
Kidney Int. 67 (2005) 1256–1267.
[57] M. Liu, S. Shi, S. Senthilnathan, J. Yu, E. Wu, C. Bergmann, K. Zerres, N. Bogdanova,
E. Coto, C. Deltas, A. Pierides, K. Demetriou, O. Devuyst, B. Gitomer, M. Laakso, A.
Lumiaho, K. Lamnissou, R. Magistroni, P. Parfrey, M. Breuning, D.J. Peters, R.
Torra, C.G. Winearls, V.E. Torres, P.C. Harris, A.D. Paterson, Y. Pei, Genetic
variation of DKK3 may modify renal disease severity in ADPKD, J. Am. Soc.
Nephrol. 21 (2010) 1510–1520.
[58] S. Rossetti, P.C. Harris, Genotype-phenotype correlations in autosomal dominant
and autosomal recessive polycystic kidney disease, J. Am. Soc. Nephrol. 18
(2007) 1374–1380.
[59] A.M. Gout, N.C. Martin, A.F. Brown, D. Ravine, PKDB: polycystic kidney disease
mutation database—a gene variant database for autosomal dominant polycystic
kidney disease, Hum. Mutat. 28 (2007) 654–659.
[60] S. Rossetti, M.B. Consugar, A.B. Chapman, V.E. Torres, L.M. Guay-Woodford, J.J.
Grantham,W.M. Bennett, C.M.Meyers, D.L.Walker, K. Bae, Q.J. Zhang, P.A. Thompson,
J.P. Miller, P.C. Harris, Comprehensive molecular diagnostics in autosomal dominant
polycystic kidney disease, J. Am. Soc. Nephrol. 18 (2007) 2143–2160.
[61] A.B. Chapman, L.M. Guay-Woodford, J.J. Grantham, V.E. Torres, K.T. Bae, D.A.
Baumgarten, P.J. Kenney, B.F. King Jr., J.F. Glockner, L.H. Wetzel, M.E. Brummer,W.C. O'Neill, M.L. Robbin, W.M. Bennett, S. Klahr, G.H. Hirschman, P.L. Kimmel, P.A.
Thompson, J.P. Miller, Renal structure in early autosomal-dominant polycystic
kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of
Polycystic Kidney Disease (CRISP) cohort, Kidney Int. 64 (2003) 1035–1045.
[62] Y.C. Tan, J.D. Blumenfeld, R. Anghel, S. Donahue, R. Belenkaya, M. Balina, T.
Parker, D. Levine, D.G. Leonard, H. Rennert, Novel method for genomic analysis of
PKD1 and PKD2 mutations in autosomal dominant polycystic kidney disease,
Hum. Mutat. 30 (2009) 264–273.
[63] S. Rossetti, L. Strmecki, V. Gamble, S. Burton, V. Sneddon, B. Peral, S. Roy, A. Bakkaloglu,
R. Komel, C.G.Winearls, P.C.Harris,Mutation analysis of the entire PKD1gene: genetic
and diagnostic implications, Am. J. Hum. Genet. 68 (2001) 46–63.
[64] R.T. Blaszak, V. Potaman, R.R. Sinden, J.J. Bissler, DNA structural transitions
within the PKD1 gene, Nucleic Acids Res. 27 (1999) 2610–2617.
[65] T.J.Watnick,M.A.Gandolph,H.Weber,H.P.Neumann,G.G.Germino,Gene conversion
is a likely cause of mutation in PKD1, Hum. Mol. Genet. 7 (1998) 1239–1243.
[66] K. Wang, X. Zhao, S. Chan, O. Cil, N. He, X. Song, A.D. Paterson, Y. Pei, Evidence for
pathogenicity of atypical splice mutations in autosomal dominant polycystic
kidney disease, Clin. J. Am. Soc. Nephrol. 4 (2009) 442–449.
[67] K. Hackmann, A. Markoff, F. Qian, N. Bogdanova, G.G. Germino, P. Pennekamp, B.
Dworniczak, J. Horst, V. Gerke, A splice form of polycystin-2, lacking exon 7, does
not interact with polycystin-1, Hum. Mol. Genet. 14 (2005) 3249–3262.
[68] C. Lohning, U. Nowicka, A.M. Frischauf, The mouse homolog of PKD1: sequence
analysis and alternative splicing, Mamm. Genome 8 (1997) 307–311.
[69] H. Xu, J. Shen, C.L.Walker, E. Kleymenova, Tissue-speciﬁc expression and splicing
of the rat polycystic kidney disease 1 gene, DNA Seq. 12 (2001) 361–366.
[70] Y.C. Tan, J. Blumenfeld, A. Michaeel, S. Donahue, M. Balina, T. Parker, D. Levine, H.
Rennert, Aberrant PKD2 splicing due to a presumed novel missense mutation
in autosomal-dominant polycystic kidney disease, Clin. Genet. (2010), doi:
10.1111/j.1399-0004.2010.01555.x8 [Epub ahead of print].
[71] R.C. Lee, R.L. Feinbaum, V. Ambros, The C. elegans heterochronic gene lin-4
encodes small RNAs with antisense complementarity to lin-14, Cell 75 (1993)
843–854.
[72] E.A. Miska, How microRNAs control cell division, differentiation and death, Curr.
Opin. Genet. Dev. 15 (2005) 563–568.
[73] S. Grifﬁths-Jones, H.K. Saini, S. van Dongen, A.J. Enright, miRBase: tools for
microRNA genomics, Nucleic Acids Res. 36 (2008) D154–D158.
[74] R.C. Friedman, K.K. Farh, C.B. Burge, D.P. Bartel, Most mammalian mRNAs are
conserved targets of microRNAs, Genome Res. 19 (2009) 92–105.
[75] B.P. Lewis, C.B. Burge, D.P. Bartel, Conserved seed pairing, often ﬂanked by
adenosines, indicates that thousands of human genes are microRNA targets, Cell
120 (2005) 15–20.
[76] S.O. Lee, T. Masyuk, P. Splinter, J.M. Banales, A. Masyuk, A. Stroope, N. Larusso,
MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and
affects hepatic cystogenesis in a rat model of polycystic kidney disease, J. Clin.
Invest. 118 (2008) 3714–3724.
[77] N. Gretz, B. Kranzlin, R. Pey, G. Schieren, J. Bach, N. Obermuller, I. Ceccherini, I.
Kloting, P. Rohmeiss, S. Bachmann, M. Hafner, Rat models of autosomal dominant
polycystic kidney disease, Nephrol. Dial. Transplant. 11 (Suppl 6) (1996) 46–51.
[78] P. Pandey, B. Brors, P.K. Srivastava, A. Bott, S.N. Boehn, H.J. Groene, N. Gretz,
Microarray-based approach identiﬁes microRNAs and their target functional
patterns in polycystic kidney disease, BMC Genomics 9 (2008) 624.
[79] G.J. Hurteau, S.D. Spivack, G.J. Brock, Potential mRNA degradation targets of hsa-
miR-200c, identiﬁed using informatics and qRT-PCR, Cell Cycle 5 (2006)
1951–1956.
[80] H. Sun, Q.W. Li, X.Y. Lv, J.Z. Ai, Q.T. Yang, J.J. Duan, G.H. Bian, Y. Xiao, Y.D. Wang, Z.
Zhang, Y.H. Liu, R.Z. Tan, Y. Yang, Y.Q. Wei, Q. Zhou, MicroRNA-17 post-
transcriptionally regulates polycystic kidney disease-2 gene and promotes cell
proliferation, Mol. Biol. Rep. (2009).
[81] U. Tran, L. Zakin, A. Schweickert, R. Agrawal, R. Doger, M. Blum, E.M. De Robertis,
O. Wessely, The RNA-binding protein bicaudal C regulates polycystin 2 in the
kidney by antagonizing miR-17 activity, Development 137 (2010) 1107–1116.
[82] G. Aguiari, S. Savelli, M. Garbo, A. Bozza, G. Augello, L. Penolazzi, E. De Paoli Vitali, C.
La Torre, G. Cappelli, R. Piva, L. del Senno, Novel splicing andmissensemutations in
autosomal dominant polycystic kidney disease 1 (PKD1) gene: expression of
mutated genes, Hum. Mutat. 16 (2000) 444–445.
[83] S. Burtey, A.M. Lossi, J. Bayle, Y. Berland, M. Fontes, Mutation screening of the
PKD1 transcript by RT-PCR, J. Med. Genet. 39 (2002) 422–429.
[84] D. Ravine, R.N. Gibson, R.G. Walker, L.J. Shefﬁeld, P. Kincaid-Smith, D.M. Danks,
Evaluation of ultrasonographic diagnostic criteria for autosomal dominant
polycystic kidney disease 1, Lancet 343 (1994) 824–827.
[85] Y. Pei, J. Obaji, A. Dupuis, A.D. Paterson, R. Magistroni, E. Dicks, P. Parfrey, B.
Cramer, E. Coto, R. Torra, J.L. San Millan, R. Gibson, M. Breuning, D. Peters, D.
Ravine, Uniﬁed criteria for ultrasonographic diagnosis of ADPKD, J. Am. Soc.
Nephrol. 20 (2009) 205–212.
[86] C. Nicolau, R. Torra, C. Badenas, R. Vilana, L. Bianchi, R. Gilabert, A. Darnell, C. Bru,
Autosomal dominant polycystic kidney disease types 1 and 2: assessment of US
sensitivity for diagnosis, Radiology 213 (1999) 273–276.
[87] J.D. Blumenfeld, Pretransplant genetic testing of live kidney donors at risk for
autosomal dominant polycystic kidney disease, Transplantation 87 (2009)
6–7.
[88] E. Huang, M. Samaniego-Picota, T. McCune, J.K. Melancon, R.A. Montgomery, R.
Ugarte, E. Kraus, K. Womer, H. Rabb, T. Watnick, DNA testing for live kidney
donors at risk for autosomal dominant polycystic kidney disease, Transplanta-
tion 87 (2009) 133–137.
[89] Y. Pei, Diagnostic approach in autosomal dominant polycystic kidney disease,
Clin. J. Am. Soc. Nephrol. 1 (2006) 1108–1114.
1212 Y.-C. Tan et al. / Biochimica et Biophysica Acta 1812 (2011) 1202–1212[90] M. De Rycke, I. Georgiou, K. Sermon, W. Lissens, P. Henderix, H. Joris, P. Platteau,
A. Van Steirteghem, I. Liebaers, PGD for autosomal dominant polycystic kidney
disease type 1, Mol. Hum. Reprod. 11 (2005) 65–71.
[91] M.A. Garcia-Gonzalez, J.G. Jones, S.K. Allen, C.M. Palatucci, S.D. Batish, W.K.
Seltzer, Z. Lan, E. Allen, F. Qian, X.M. Lens, Y. Pei, G.G. Germino, T.J. Watnick,
Evaluating the clinical utility of a molecular genetic test for polycystic kidney
disease, Mol. Genet. Metab. 92 (2007) 160–167.
[92] R.A. Perrichot, B. Mercier, P.M. Simon, B. Whebe, J. Cledes, C. Ferec, DGGE
screening of PKD1 gene reveals novelmutations in a large cohort of 146 unrelated
patients, Hum. Genet. 105 (1999) 231–239.
[93] R. Perrichot, B. Mercier, I. Quere, A. Carre, P. Simon, B. Whebe, J. Cledes, C. Ferec,
Novel mutations in the duplicated region of PKD1 gene, Eur. J. Hum. Genet.
8 (2000) 353–359.
[94] B. Veldhuisen, J.J. Saris, S. de Haij, T. Hayashi, D.M. Reynolds, T. Mochizuki, R.
Elles, R. Fossdal, N. Bogdanova, M.A. van Dijk, E. Coto, D. Ravine, S. Norby, C.
Verellen-Dumoulin, M.H. Breuning, S. Somlo, D.J. Peters, A spectrum of
mutations in the second gene for autosomal dominant polycystic kidney disease
(PKD2), Am. J. Hum. Genet. 61 (1997) 547–555.
[95] T. Watnick, G.G. Germino, Molecular basis of autosomal dominant polycystic
kidney disease, Semin. Nephrol. 19 (1999) 327–343.
[96] B. Phakdeekitcharoen, T.J. Watnick, G.G. Germino, Mutation analysis of the entire
replicated portion of PKD1 using genomic DNA samples, J. Am. Soc. Nephrol. 12
(2001) 955–963.
[97] S. Zhang, C. Mei, D. Zhang, B. Dai, B. Tang, T. Sun, H. Zhao, Y. Zhou, L. Li, Y. Wu, W.
Wang, X. Shen, J. Song, Mutation analysis of autosomal dominant polycystic kidney
disease genes in Han Chinese, Nephron Exp. Nephrol. 100 (2005) e63–e76.
[98] S. Rossetti, D. Chauveau, D. Walker, A. Saggar-Malik, C.G. Winearls, V.E. Torres, P.C.
Harris, A complete mutation screen of the ADPKD genes by DHPLC, Kidney Int. 61
(2002) 1588–1599.
[99] A.R. Quinlan, G.T. Marth, Primer-site SNPs mask mutations, Nat. Meth. 4 (2007) 192.
[100] Y. Ariyurek, I. Lantinga-van Leeuwen, L. Spruit, D. Ravine, M.H. Breuning, D.J.
Peters, Large deletions in the polycystic kidney disease 1 (PKD1) gene, Hum.
Mutat. 23 (2004) 99.
[101] P. Kozlowski, J. Bissler, Y. Pei, D.J. Kwiatkowski, Analysis of PKD1 for genomic
deletion by multiplex ligation-dependent probe assay: absence of hot spots,
Genomics 91 (2008) 203–208.
[102] M.B. Consugar, W.C. Wong, P.A. Lundquist, S. Rossetti, V.J. Kubly, D.L. Walker, L.J.
Rangel, R. Aspinwall, W.P. Niaudet, S. Ozen, A. David, M. Velinov, E.J. Bergstralh,K.T. Bae, A.B. Chapman, L.M. Guay-Woodford, J.J. Grantham, V.E. Torres, J.R.
Sampson, B.D. Dawson, P.C. Harris, Characterization of large rearrangements in
autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous
gene syndrome, Kidney Int. 74 (2008) 1468–1479.
[103] R. Grantham, Amino acid difference formula to help explain protein evolution,
Science 185 (1974) 862–864.
[104] S.V. Tavtigian, A.M. Deffenbaugh, L. Yin, T. Judkins, T. Scholl, P.B. Samollow, D. de
Silva, A. Zharkikh, A. Thomas, Comprehensive statistical study of 452 BRCA1
missense substitutions with classiﬁcation of eight recurrent substitutions as
neutral, J. Med. Genet. 43 (2006) 295–305.
[105] E. Mathe, M. Olivier, S. Kato, C. Ishioka, P. Hainaut, S.V. Tavtigian, Computational
approaches for predicting the biological effect of p53 missense mutations: a
comparison of three sequence analysis based methods, Nucleic Acids Res. 34
(2006) 1317–1325.
[106] P.C. Ng, S. Henikoff, Predicting deleterious amino acid substitutions, Genome Res.
11 (2001) 863–874.
[107] P.C. Ng, S. Henikoff, Accounting for human polymorphisms predicted to affect
protein function, Genome Res. 12 (2002) 436–446.
[108] S. Sunyaev, V. Ramensky, I. Koch, W. Lathe 3rd, A.S. Kondrashov, P. Bork,
Prediction of deleterious human alleles, Hum. Mol. Genet. 10 (2001) 591–597.
[109] V. Ramensky, P. Bork, S. Sunyaev, Human non-synonymous SNPs: server and
survey, Nucleic Acids Res. 30 (2002) 3894–3900.
[110] M.G. Reese, F.H. Eeckman, D. Kulp, D. Haussler, Improved splice site detection in
Genie, J. Comput. Biol. 4 (1997) 311–323.
[111] L. Cartegni, J. Wang, Z. Zhu, M.Q. Zhang, A.R. Krainer, ESEﬁnder: a web resource
to identify exonic splicing enhancers, Nucleic Acids Res. 31 (2003) 3568–3571.
[112] F.O. Desmet, D. Hamroun, M. Lalande, G. Collod-Beroud, M. Claustres, C. Beroud,
Human Splicing Finder: an online bioinformatics tool to predict splicing signals,
Nucleic Acids Res. 37 (2009) e67.
[113] K. King, F.A. Flinter, V. Nihalani, P.M. Green, Unusual deep intronic mutations
in the COL4A5 gene cause X linked Alport syndrome, Hum. Genet. 111 (2002)
548–554.
[114] M.C. Daoust, D.M. Reynolds, D.G. Bichet, S. Somlo, Evidence for a third genetic
locus for autosomal dominant polycystic kidney disease, Genomics 25 (1995)
733–736.
[115] S. de Almeida, E. de Almeida, D. Peters, J.R. Pinto, I. Tavora, J. Lavinha, M. Breuning,
M.M. Prata, Autosomal dominant polycystic kidney disease: evidence for the
existence of a third locus in a Portuguese family, Hum. Genet. 96 (1995) 83–88.
